FDA Accepts Oyster Point's Varenicline Nasal Spray Application For Review In Dry Eye Disease
- The FDA has accepted Oyster Point Pharma Inc's (NASDAQ: OYST) marketing application for review. It seeks approval for OC-01 (varenicline) nasal spray to treat signs and symptoms of dry eye disease.
- The target date is October 17.
- At present, FDA has stated that it does not intend to hold an advisory committee meeting for this application.
- OC-01 (varenicline) nasal spray is a highly selective cholinergic agonist.
- Price Action: OYST shares closed 2.2% higher at $20.25 on Monday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: dry eye diseaseBiotech News Health Care Small Cap FDA General
